Table 1:
Baseline characteristics of study cohorts (n=72)
| Variable | Frequency | Percentage |
|---|---|---|
| Age, in years | ||
| <50 | 24 | 33.3 |
| ≥50 | 48 | 66.7 |
| Mean age±SD=54.6±10.7 years | ||
| Menopausal status | ||
| Premenopausal | 33 | 45.8 |
| Postmenopausal | 39 | 54.2 |
| Parity | ||
| Low parity (≤1) | 23 | 31.9 |
| High parity (≥2) | 49 | 68.1 |
| Median parity (interquartile range [IQR]) = 2.0 (1.0, 4.0) | ||
| Body mass index (BMI), in kg/m2 | ||
| ≤25.0 | 37 | 51.4 |
| >25.0 | 35 | 48.6 |
| Median BMI (IQR) = 24.7 (22.1, 28.9) kg/m2 | ||
| Co-morbidity | ||
| No | 55 | 76.4 |
| Yes | 17 | 23.6 |
| Pretreatment CA-125 levels, in U/mL | ||
| <250 | 25 | 34.7 |
| ≥250 | 47 | 65.3 |
| Median CA125 (IQR) = 437.0 (144.0, 924.5) U/mL | ||
| Type of cytoreductive surgery | ||
| Optimal | 37 | 51.4 |
| Suboptimal | 35 | 48.6 |
| Presence of significant ascites | ||
| No | 37 | 51.4 |
| Yes | 35 | 48.6 |
| FIGO stage | ||
| Early (I-II) | 19 | 26.4 |
| Advanced (III-IV) | 53 | 73.6 |
| Tumour grade | ||
| Low grade (grade I) | 20 | 27.8 |
| High grade (grade II-III) | 52 | 72.2 |
| Histological type | ||
| Serous | 48 | 66.7 |
| Non-serous | 24 | 33.3 |
| Type of primary treatment | ||
| Primary debulking | 39 | 54.2 |
| Neoadjuvant chemotherapy | 33 | 45.8 |
| Thrombocytosis | ||
| No | 42 | 58.3 |
| Yes | 30 | 41.7 |
| Median platelet counts (IQR) = 428 (301, 503) × 109/L | ||
| Recurrence within 36 months | ||
| Yes | 55 | 76.4 |
| No | 17 | 23.6 |
| Median PFS (IQR) = 15.0 (8.0, 29.5) months | ||
| Vital status at 36-months | ||
| Dead | 27 | 37.5 |
| Alive | 45 | 62.5 |
Median OS (IQR) 36.0 (23.0, 36.0) months. SD: standard deviation; IQR: interquartile range; PFS: progression-free survival; OS: Overall survival; FIGO: International Federation of Obstetrics and Gynecology